Search Results - "HAY, C. R. M"

The impact of sport on health status, psychological well-being and physical performance of adults with haemophilia by von Mackensen, S., Harrington, C., Tuddenham, E., Littley, A., Will, A., Fareh, M., Hay, C. R. M., Khair, K.

“…Background There is increasing recognition that sport is important for individuals with haemophilia; however, there remains a paucity of data of the importance…”
Get full text

Evaluation of the use of global haemostasis assays to monitor treatment in factor XI deficiency by Pike, G. N., Cumming, A. M., Thachil, J., Hay, C. R. M., Burthem, J., Bolton‐Maggs, P. H. B.

“…Introduction Previous guidelines recommend that FXI:C levels should be used to monitor FXI replacement in factor XI (FXI) deficiency. However, FXI:C levels do…”
Get full text

Inhibitor treatment in haemophilias A and B: summary statement for the 2006 international consensus conference by BERNTORP, E., SHAPIRO, A., ASTERMARK, J., BLANCHETTE, V. S., COLLINS, P. W., DIMICHELE, D., ESCURIOLA, C., HAY, C. R. M., HOOTS, W. K., LEISSINGER, C. A., NEGRIER, C., OLDENBURG, J., PEERLINCK, K., REDING, M. T., HART, C.

“…Participants in an international conference on the management of haemophilia patients with inhibitors developed a jointly authored summary of the findings and…”
Get full text

The diagnosis and management of factor VIII and IX inhibitors : A guideline from the UK Haemophilia Centre Doctors' Organization (UKHCDO) by HAY, C. R. M, BAGLIN, T. P, COLLINS, P. W, HILL, F. G. H, KEELING, D. M

Get full text

Development of resistance to activated protein C during pregnancy by Cumming, A M, Tait, R C, Fildes, S, Yoong, A, Keeney, S, Hay, C R

“…We measured activated protein C (APC) anticoagulant activity in 20 healthy women at 14-20, 28 and 36 weeks gestation, and at 1 d post-partum. Significant…”
Get more information

Purchasing factor concentrates in the 21st century through competitive tendering by Hay, C. R. M.

“…Summary The increasing intensity of treatment, the widespread adoption of factor VIII and IX prophylaxis and increasing usage over the past decade have led to…”
Get full text

The haemtrack home therapy reporting system: Design, implementation, strengths and weaknesses: A report from UK Haemophilia Centre Doctors Organisation by Hay, C. R. M., Xiang, H., Scott, M., Collins, P. W., Liesner, R., Dolan, G., Hollingsworth, R.

“…Introduction Haemtrack is an electronic home treatment diary for patients with inherited bleeding disorders, introduced in 2008. It aimed to improve the…”
Get full text

Use of the UKHCDO Database for a postmarketing surveillance study of different doses of recombinant factor VIIa in haemophilia by Hay, C. R. M., Sharpe, T., Dolan, G.

“…Introduction Recombinant factor VIIa (rFVIIa) is recommended in Europe at standard (3 × 90 μg kg−1) or high (1 × 270 μg kg−1) doses. When granting the license…”
Get full text

The immunogenicity of ReFacto AF (moroctocog alfa AF‐CC) in previously untreated patients with haemophilia A in the United Kingdom by Mathias, M. C., Collins, P. W., Palmer, B. P., Chalmers, E., Alamelu, J., Richards, M., Will, A., Hay, C. R. M.

“…Introduction Factor VIII inhibitor development is currently the most serious complication of the treatment of haemophilia A. Differences in manufacturing and…”
Get full text

Weekly recombinant FIX prophylaxis for severe haemophilia B in normal clinical practice: data from UKHCDO and Finland by Scott, M., Nummi, V., Lassila, R., Xiang, H., Hay, C. R. M.

Get full text

Pharmacokinetics, safety and efficacy of a recombinant factor IX product, trenonacog alfa in previously treated haemophilia B patients by Collins, P. W., Quon, D. V. K., Makris, M., Chowdary, P., Kempton, C. L., Apte, S. J., Ramanan, M. V., Hay, C. R. M., Drobic, B., Hua, Y., Babinchak, T. J., Gomperts, E. D.

“…Introduction Trenonacog alfa (IB1001) is a recombinant factor IX (rFIX) manufactured in Chinese hamster ovary (CHO) cells. IB1001 was evaluated in a…”
Get full text

The incidence of factor VIII inhibitors in severe haemophilia A following a major switch from full-length to B-domain-deleted factor VIII: a prospective cohort comparison by Hay, C. R. M., Palmer, B. P., Chalmers, E. A., Hart, D. P., Liesner, R., Rangarajan, S., Talks, K., Williams, M., Collins, P. W.

“…Summary Although it has been suggested that switching of factor VIII (FVIII) products may increase inhibitor formation this is disputed. Half of UK patients…”
Get full text

Recommendations for the treatment of factor VIII inhibitors: from the UK Haemophilia Centre Directors' Organisation Inhibitor Working Party by Hay, C R, Colvin, B T, Ludlam, C A, Hill, F G, Preston, F E

“…A strategy is described for the initial detection, management and elimination of factor VIII inhibitors arising in patients with congenital and acquired…”
Get more information

EUHASS: The European Haemophilia Safety Surveillance system by Makris, M, Calizzani, G, Fischer, K, Gilman, E.A, Hay, C.R.M, Lassila, R, Lambert, T, Ludlam, C.A, Mannucci, P.M

“…Abstract Pharmacovigilance is an essential element of any drug treatment and considering the history of adverse events due to products used to treat inherited…”
Get full text

Efficacy and safety of Nuwiq® (human‐cl rhFVIII) in patients with severe haemophilia A undergoing surgical procedures by Zozulya, N., Kessler, C. M., Klukowska, A., Depka, M., Hampton, K., Hay, C. R. M., Jansen, M., Bichler, J., Knaub, S., Rangarajan, S.

“…Introduction Haemophilia A patients are at a high risk of excess bleeding during surgeries. The aim of haemostatic therapy during the perioperative period is…”
Get full text

Central venous access device (CVAD) complications in Haemophilia with inhibitors undergoing immune tolerance induction: Lessons from the international immune tolerance study by Rodriguez, V., Mancuso, M. E., Warad, D., Hay, C. R. M., DiMichele, D. M., Valentino, L., Kenet, G., Kulkarni, R.

“…Introduction Central venous access devices (CVADs) are frequently required as stable long‐lasting venous access in children with haemophilia, especially those…”
Get full text

Prophylaxis in adults with haemophilia by HAY, C. R. M.

“…  The indications for and the efficacy of prophylaxis in adults with haemophilia remain controversial. It is unclear whether the benefits of secondary…”
Get full text

Tamoxifen for recurrent bleeds due to angiodysplasia in von Willebrand's disease by Thachil, J., Hay, C. R. M., Campbell, S.

Get full text

The incidence of factor VIII and factor IX inhibitors in the hemophilia population of the UK and their effect on subsequent mortality, 1977–99 by Darby, S. C., Keeling, D. M., Spooner, R. J. D., Wan Kan, S., Giangrande, P. L. F., Collins, P. W., Hill, F. G. H., Hay, C. R. M.

“…Background: Previous studies of the development of inhibitors and their impact on mortality have been small. Objectives: To examine the development of…”
Get full text

Evaluation of the use of rotational thromboelastometry in the assessment of FXI deficency by Pike, G. N., Cumming, A. M., Thachil, J., Hay, C. R. M., Bolton‐Maggs, P. H. B., Burthem, J.

“…Introduction The absence of a reliable clinical test to predict bleeding tendency leaves factor XI (FXI)‐deficient individuals at risk of overtreatment or…”
Get full text